Phil. Thanks,
update. and expanded Earlier quick this oral met expansion for trial that Regarding the company trial. TPOXX targets year program enrollment the label as noted safety for immunogenicity the we background a PEP the both
safety the became trial, recently results expanded trial For the clinical available.
expected, events. As serious did drug-related any see we adverse not
Jynneos that that of was not trial vaccine immune preliminary vaccine. vaccine a the immunogenicity did the goal the small as the received reduce postbox consistent show approval of data, while not response trial a that placebo and of analysis treatment to of current we the This plus do see while the TPOXX, pox. In this TPOXX Jynneos to trial separate For meaningful the quick supplemental TPOXX for which what on Jynneos is difference received those the to with our those immunogenicity the is the on we compared between expected. with reminder,
to both measurable expected. At point response For into reasons, investigations we understand, don't the pending of had the further as do the volunteers that originally TPOXX numbers the number this and lower-than-expected effects was in trial. of the Jynneos groups points to have immune the determination non-inferiority vaccine of the or placebo in a endpoint -- currently number the make data lower number planned immunogenicity not than is the responders that currently time, we sufficient statistical of as primary lower
showing who immune the safety or immune response response why vaccine. the of generating investigating a about those are percentage efficacy we the investigating of To we're to are nor about immune TPOXX TPOXX's not volunteers, overall be impact are individuals saw The We're of the analyses lower an an clear, response. on to levels they vaccine. volunteers
an provide the the of plan lower-than-expected through rate. stockpile extra processes for data expansion data, response government. conversations, investigate In trial, to work review to reasons It's terms and context maximum effort call getting a of immunogenicity or the and next the most worth on overall and clinical in update the available. timely becomes investor fully the when benefit time from We with of the trial
we comments the to the clinical and been use As the I program, regard contextual trial review challenge FDA. totality that of note previous supportive experiment immunogenicity gears, in before PEP, have believe studies well shift that trials I'd that like TPOXX of the and are conducted, discussion animal as PEP for the with to including trials as and in the pending
for randomized studies PEP an in the collect reduce controlled morbidity the or important enroll be epidemic, to observation use With of as orthopox of well as case Mpox population. to trials respect Mpox the continue multiple trials, and will In and five data. smallpox, mortality it be TPOXX to patients
the example, the X enrolled in had NIAID patients. of PALM had deducted XXX NIAID August as and patients being trial DRC trial enrolled the For XXX STOMP
the this been agencies with coordinate government case will trials. summer While Mpox act in summer, mild to RCTs of last has observational and count to continue comparison we the on
call, are is aggregation an of of it for RCTs their with idea investor as data As subject the reaching potentially sufficient evaluation. unblinded, noted last contemplating in numbers the regulatory
in the what case of cases there scenarios While United believe or is other countries when We periodically. unknown deal the the years. will and to be need Mpox ultimate across that world, we levels the as States with in uncertain, the It's for is path consistent high come that levels scope just will the to short-term have probability cases. there the magnitude continue the Mpox outbreak The different most communities, and of a future of is across where a case believe TPOXX. become and go that cases to the the
to At to this financial the a turn update. Dan for I'd call over like point,
